Dr. Wilson H. Miller is a Professor in Oncology and
Medicine at McGill University and the Director at the Clinical Research Unit,
Jewish General Hospital. Dr. Miller obtained his PhD in cell biology from the
Rockefeller University, and an MD from Cornell University. He completed a
fellowship in medical oncology at New York’s Memorial Sloan-Kettering Cancer
Center (MSKCC), and held faculty appointments in the Department of Medicine at
Cornell, as well as at MSKCC. He joined McGill as an Associate Professor
jointly in Oncology and Medicine in 1993 and was named James McGill Professor
in 2004, the latter being a distinction reserved for the top 10% of senior researchers
at McGill. His clinical focus is on melanoma, breast and renal cancer, and in
championing clinical trials at the JGH and at McGill, where he serves as
Director of the Phase I Clinical Research Unit. His basic science focus is on
investigating the molecular mechanisms underlying hematologic cancer, melanoma
and breast cancer, with a focus on the development of novel targeted therapies.
He sits on peer review panels for the National Institutes of Health (US), the
Canadian Institute of Health Research, the Ontario Cancer Research Network, and
the Leukemia Lymphoma Society.
Dr. Wilson H. Miller is a Professor in Oncology and
Medicine at McGill University and the Director at the Clinical Research Unit,
Jewish General Hospital. Dr. Miller obtained his PhD in cell biology from the
Rockefeller University, and an MD from Cornell University. He completed a
fellowship in medical oncology at New York’s Memorial Sloan-Kettering Cancer
Center (MSKCC), and held faculty appointments in the Department of Medicine at
Cornell, as well as at MSKCC. He joined McGill as an Associate Professor
jointly in Oncology and Medicine in 1993 and was named James McGill Professor
in 2004, the latter being a distinction reserved for the top 10% of senior researchers
at McGill. His clinical focus is on melanoma, breast and renal cancer, and in
championing clinical trials at the JGH and at McGill, where he serves as
Director of the Phase I Clinical Research Unit. His basic science focus is on
investigating the molecular mechanisms underlying hematologic cancer, melanoma
and breast cancer, with a focus on the development of novel targeted therapies.
He sits on peer review panels for the National Institutes of Health (US), the
Canadian Institute of Health Research, the Ontario Cancer Research Network, and
the Leukemia Lymphoma Society.